c-LEcta Accelerates Distribution of DENARASE® and Signs Sales Agreement With VWR
c-LEcta, a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma, strengthens the product marketing of its patented nuclease enzyme DENARASE ® through a sales cooperation with VWR, a global trading company for laboratory supplies. DENARASE ® offers more efficient production processes for biopharmaceuticals and has market potential in the double-digit million-euro range.
To continue its growth strategy, c-LEcta is further expanding its track record in the commercialization of its products. In addition to the recent successes in the food sector, the company is now pushing the accelerated product marketing in the pharma industry. The German industrial biotechnology expert has signed an agreement with VWR, an international laboratory supplies trading company, to sell its DENARASE® product. The product, which was mainly marketed by c-LEcta itself, will make a significant contribution to the company's sales in the current fiscal year 2018. Through the cooperation with VWR, c-LEcta is now addressing customers in the life science sector in an even more targeted manner. VWR is an important source of raw materials for these customers.
DENARASE® is a nuclease enzyme. It helps to remove genetic information carriers (nucleic acids; DNA and RNA) from the production process of biopharmaceuticals. The complete removal of nucleic acids from biopharmaceutical products is necessary to meet the high regulatory requirements for these products. The production process of the enzyme is patented. DENARASE® is currently the most efficient technology on the market for removing nucleic acids. This considerably simplifies the production process, reduces follow-up costs to a competitive level and ensures reliable availability. The manufacturing process meets the highest quality requirements of cGMP (current Good Manufacturing Practice) and thus meets the high demands of pharmaceutical manufacturers.
In the pharmaceutical industry, DENARASE® is used in multiple areas. A large share currently falls on the established vaccine market. Here c-LEcta is already active as a supplier for pharmaceutical companies. Another field for DENARASE® is the development and fabrication of components for use in cell and gene therapy. According to estimates by c-LEcta, the marketing of DENARASE® has a worldwide market potential in the double-digit million-euro range.
CEO Marc Struhalla: "With DENARASE®, we enable higher efficiencies in production processes than in conventional approaches and also set new standards in quality. In terms of price/performance ratio, we are thus offering the pharmaceutical industry a very attractive offer for optimizing their manufacturing procedures. The combination of our product innovation and VWR's access to the life science sector gives us the best prerequisites for gaining additional market share in a very dynamic market. We expect additional sales in the millions as an important contribution to our strong growth."
c-LEcta is a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma. The company is located in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry partners. The company currently employs approximately 60 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
cometis AG for c-LEcta
Phone: +49 (0) 611 - 205855 – 22
Fax: +49 (0) 611 - 205855 – 66
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hologic Enters into Exclusive Negotiations to Acquire SuperSonic Imagine, French Ultrasound Innovator20.6.2019 20:01:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end. “Like our previous acquisitions of Faxitron and Focal, acquiring SuperSonic Imagine will strengthen our strategy to provide comprehensive screening, interventional and surgical solutions across the continuum of breast health care,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “Ultrasound is becoming increasingly important in diagnosing breast cancer, and we believe SuperSonic Imagine offers superior technology that translates into better clinical outcomes for breast cancer patients, as well as for patients with liver and prostate disease.” Under the terms of
Digital Transformation Gets Bigger, Better, Bolder at LiveWorx’1920.6.2019 17:54:00 CEST | Pressemelding
A record crowd gathered in Boston last week for the annual LiveWorx® digital transformation event, where attendees explored how digital transformation is becoming a reality for an ever-increasing number of manufacturing companies around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190620005610/en/ The annual LiveWorx event brought together more than 6,400 of the industry’s greatest minds from more than 40 countries (with approximately 7,000 more live-streaming the event) with content spanning disruptive technologies including AR, IIoT, Industry 4.0 and more. LiveWorx 2020 will take place between June 8-11 in Boston's Innovation District. The event brought together more than 6,400 of the industry’s greatest minds from more than 40 countries (with approximately 7,000 more live-streaming the event) for four days of interactive workshops, facilitated industry networking, cutting-edge demos featuring the latest enter
INSERTING and REPLACING Arch Capital Group Names Seamus Fearon EVP, Credit Risk Transfer and Services, Global Mortgage Group20.6.2019 16:47:00 CEST | Pressemelding
Insert at end of first sentence of release: subject to regulatory approval. The corrected release reads: ARCH CAPITAL GROUP NAMES SEAMUS FEARON EVP, CREDIT RISK TRANSFER AND SERVICES, GLOBAL MORTGAGE GROUP Arch Capital Group Ltd. (Arch) today announced that Seamus Fearon has been promoted to Executive Vice President, Credit Risk Transfer and Services, Global Mortgage Group, subject to regulatory approval. In this role, Fearon will have responsibility for managing Arch’s credit risk transfer (CRT) business and growing its credit risk services offerings. He most recently was Chief Actuary of Arch’s Global Mortgage Group, where he oversaw its capital management framework and the development of its analytics and modeling capabilities. This newly created role highlights Arch’s focus on participating in credit risk transfer programs and supporting customers who would like to enter that growing market. “As the mortgage insurance market in the U.S. becomes even more competitive, it’s important
The “Centre Hospitalier de la Côte Basque” in France Has Started the Evaluation of the Biolog-id’s C-LOG® Solution20.6.2019 15:35:00 CEST | Pressemelding
The Centre Hospitalier de la Côte Basque (CHCB) in Bayonne has been using Biolog-id's C-LOG® solution since early April 2019. This solution secures and optimizes the circuit of chemotherapy and immunotherapy, from their preparation all the way to the administration to the patient. The C-LOG® solution has been used at the CHCB. "During the last HAS audit, a lack of traceability was revealed in the chemotherapy circuit. In order to close this gap, we decided to install the C-LOG® solution which, in addition to securing the administration to the patient's bed, makes it possible to trace the preparation circuit from the pharmacy to the reception in the nurses station," says Dr. Burtin, Pharmacist at CHCB. The solution will be tested for evaluation for 3 months before final adoption. "The RFID (Radio Frequency Identification) technology is the foundation of our solution. The tag affixed on each preparation contains the product and patient data. This information is updated in real-time and c
CSC Announces Cyber Security Findings for the Media Industry20.6.2019 15:00:00 CEST | Pressemelding
Securing a company’s digital infrastructure has become a major concern to corporations worldwide. With leading security companies and other organizations alerting corporations and the public to recent widespread, state-sponsored domain name system (DNS) hijacking, more and more brands are starting to take action. CSC has been issuing Cyber Security Reports since 2017, culling the most important information about security risks, and in particular, risks to brands that are not mitigated by a traditional firewall. The recent research conducted by CSC focuses on the media industry, revealing that 78% of global media brands use a corporate domain registrar, yet only 37% of those have a registrar lock to protect their DNS from hijacking. Recent domain hijacking, unauthorized changes, and deletion of vital domains have shown that effectively managing domain names and DNS must become a critical component for enhancing the security posture of any company with an online presence. More worrisome
Arch Capital Group Names Seamus Fearon EVP, Credit Risk Transfer and Services, Global Mortgage Group20.6.2019 13:00:00 CEST | Pressemelding
Arch Capital Group Ltd. (Arch) today announced that Seamus Fearon has been promoted to Executive Vice President, Credit Risk Transfer and Services, Global Mortgage Group. In this role, Fearon will have responsibility for managing Arch’s credit risk transfer (CRT) business and growing its credit risk services offerings. He most recently was Chief Actuary of Arch’s Global Mortgage Group, where he oversaw its capital management framework and the development of its analytics and modeling capabilities. This newly created role highlights Arch’s focus on participating in credit risk transfer programs and supporting customers who would like to enter that growing market. “As the mortgage insurance market in the U.S. becomes even more competitive, it’s important for Arch to diversify its mortgage business to ensure we remain at the forefront of the industry,” said David Gansberg, CEO of Arch’s Global Mortgage Group. “Seamus brings both an analytical perspective and business acumen to these units